Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 18-May-2013
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 7 of 7)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
17-May-13 S&P Capital IQ Quantitative Report N/A Cyclacel Pharmaceuticals 5 $57.50 View Abstract
17-May-13 New Constructs, LLC N/A CYCC: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
17-May-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-biomed/genetics 18 $207 View Abstract
12-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Cyclacel Pharmaceuticals, Inc. 41 $471.50 View Abstract
11-May-13 Pechala's Reports Frantisek Pechala CYCLACEL PHARMACEUTICALS INC (CYCC) 12-months forecast 1 $15 View Abstract
10-May-13 Ford Investor Services, Inc. N/A Industry Value Graph: ALSE , CVM , CHTP , CYCC , CUR , OXBT -- DRUGS 3 $34.50 View Abstract
10-May-13 Ford Investor Services, Inc. N/A Value Graph: CYCLACEL PHARMAC -- CYCC 1 $11.50 View Abstract

Independent Reports (Showing 1 to 7 of 7)

Release
Date Contributor Author Title Pages Price More Info
17-May-13 S&P Capital IQ Quantitative Report N/A Cyclacel Pharmaceuticals 5 $57.50 View Abstract
17-May-13 New Constructs, LLC N/A CYCC: Due Diligence Review: Forensic Earnings and Valuation 13 $25 View Abstract
17-May-13 ValuEngine, Inc. N/A ValuEngine Industry Report for Medical-biomed/genetics 18 $207 View Abstract
12-May-13 Wright Reports N/A Wright Investors Service Comprehensive Report for Cyclacel Pharmaceuticals, Inc. 41 $471.50 View Abstract
11-May-13 Pechala's Reports Frantisek Pechala CYCLACEL PHARMACEUTICALS INC (CYCC) 12-months forecast 1 $15 View Abstract
10-May-13 Ford Investor Services, Inc. N/A Industry Value Graph: ALSE , CVM , CHTP , CYCC , CUR , OXBT -- DRUGS 3 $34.50 View Abstract
10-May-13 Ford Investor Services, Inc. N/A Value Graph: CYCLACEL PHARMAC -- CYCC 1 $11.50 View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.